Furthermore, combining an IDO inhibitor (to enhance endogenous anti-tumor immune activity) with chemotherapy (to directly target tumors) has been demonstrated to be effective both in vitro and in vivo and dependent on a functioning immune system [35]. Here, IDO1 is linked to neoplasm.